

# Mesenchymal stem cells as a potential pool for cartilage tissue engineering

C. Csaki\*, P.R.A. Schneider, M. Shakibaei

*Ludwig-Maximilians-University Munich, Faculty of Medicine, Institute of Anatomy, Musculoskeletal Research Group, Pettenkoferstrasse 11, D-80336 Munich, Germany*

## Contents

Introduction . . . . .	396
Challenges in connective tissue engineering . . . . .	396
Cartilage tissue engineering . . . . .	398
Next-generation ACT . . . . .	398

---

\*Corresponding author. Tel.: +49 89 5160 4829; fax: +49 89 5160 4828.  
E-mail address: [constanze.csaki@med.uni-muenchen.de](mailto:constanze.csaki@med.uni-muenchen.de) (C. Csaki).  
URL: <http://www.en.uni-muenchen.de/index.html> (C. Csaki).

MSCs for cartilage regeneration. . . . .	399
Sources, isolation and characterization of MSCs . . . . .	399
Induction of chondrogenesis in MSCs. . . . .	402
Tissue-engineering cartilage with MSCs . . . . .	404
Cartilage repair in clinical trials . . . . .	404
Hurdles in tissue-engineering cartilage from MSCs . . . . .	405
Conclusion . . . . .	405
Acknowledgements. . . . .	405
References . . . . .	405

## Introduction

In modern medicine the terms “regenerative medicine” and “Tissue Engineering” have become key words, envisioning our ability to grow and to engineer functional tissue *in vitro* that will enable us to repair and substitute damaged or degenerated tissue *in vivo* (Caplan and Goldberg, 1999; Solchaga et al., 2001). Tissue engineering can be defined as the art of reconstructing mammalian tissue, both structurally and functionally (Hollander et al., 2006), whereas this reconstruction process may be performed entirely *in vitro*, with mature tissue being transplanted, or partially *in vitro* followed by a maturation process after transplantation *in vivo*. Here we attempt to imitate natural processes in our bodies, which, in order to survive, must be able to repair and regenerate damaged tissues by replacing them with progenitor cells that have the capacity to differentiate into the specialized cell type (Tallheden et al., 2006). Modern medicine has greatly improved our abilities in the fields of diagnosis, prevention and treatment of a range of infectious, metabolic, neurodegenerative, cardiovascular, respiratory and cancerous diseases. New understandings of embryonic development and new technical skills have led to the therapeutic approach of repairing connective tissue through tissue engineering, thus opening an entirely new starting point for cartilage repair (Cancedda et al., 2003; Caplan, 1991, 2000; Caplan et al., 1997; Short et al., 2003). The need for effective cartilage repair strategies has been rising continuously, as the increase in life expectancy in humans also leads to a major increase in rheumatoid arthritis and osteoarthritis (OA). It is estimated that more than 39 million people in the European Union and over 20 million Americans have OA and it is anticipated that by the year 2020, these numbers will have doubled. In Germany, OA has major economic consequences, creating direct and indirect costs of 8 billion Euros per annum.<sup>1</sup> As existing pharma-


ceuticals (steroids and non-steroidal anti-inflammatory drugs) are unsatisfactory as they only treat the symptoms of OA by reducing pain and inflammation, these numbers make it clear that new effective treatments for OA are of vital importance.

This article will present selected methodologies for cartilage repair and the potential usefulness of mesenchymal stem cells (MSCs) and critically evaluate their strengths and limitations in articular cartilage regeneration and tissue engineering.

## Challenges in connective tissue engineering

Tissue engineering has evolved as a new field, promising *in vitro* construction of whole transplantable tissue. Basically, three main components are required for successful tissue engineering: Firstly, a scaffold providing an adequate three-dimensional surrounding. Secondly, appropriate cells which are able to differentiate and maintain the specific cell phenotype. Thirdly, the addition of the right bioactive substances such as growth factors, cytokines or hormones as a suitable stimulus for specific lineage differentiation of the cells (Kuo et al., 2006) (Figure 1). Connective tissue injuries of the bone, tendon and cartilage represent a large fraction of trauma medicine. Although bone has a high turnover rate, is vascularised and callous formation happens rather quickly, large bone defects resulting from massive traumata, tumors or metabolic and degenerative diseases have a limited capacity for self-repair and require special treatment strategies (Kajiwara et al., 2005; Krampera et al., 2006). Although osteochondral grafts have been successfully used for several decades (Czitrom et al., 1986; Marco et al., 1993; Meyers et al., 1983), grafting is often related to donor-site morbidity, increased risk of infection from allografts, immunocompatibility, implant rejection and necrosis (Hangody and Fules, 2003). Also tendon injuries, often the consequence of

<sup>1</sup>[www.g-netz.de](http://www.g-netz.de)



**Figure 1.** The principle of tissue engineering. The concept of tissue engineering comprises three main factors: Firstly, a compatible biomaterial (A), secondly adequate cells, such as stem cells (B) and thirdly the addition of specific bioactive substances (C) enhancing appropriate cell differentiation and specific tissue formation such as bone, tendon and cartilage.

recurrent micro- or macro-traumata or the side effect of antibiotic treatment with gyrase inhibitors such as quinolones (Bosch, 2000; Hankemeier et al., 2007; Sendzik et al., 2005; Shakibaei et al., 2000, 2001a; Shakibaei and Stahlmann, 2001, 2003) present another major clinical problem, as tendon, like cartilage, is a bradytroph tissue with slow and very limited regenerative capacities (Beris et al., 2005; Moller et al., 2000; Schulze-Tanzil et al., 2004a; Ahmed et al., 1998). Furthermore, the tendon also contains very few cells, the tenocytes, which produce a highly specialized extracellular matrix (ECM) (Canty and Kadler, 2002; Kannus, 2000; Rees et al., 2000). As with bone, the present regeneration strategies for tendon repair evolve around allo- and autografting of tendon; however, recently, treatments have been expanded by novel tissue-engineering approaches using bio-compatible and bio-degradable scaffolds in combination with tenocytes or MSCs (Krampera et al., 2006). The specific characteristics of articular cartilage are mainly due to the special construction of its ECM. The ECM is produced by the cartilage cells, the chondrocytes, which make up less than 5% of the tissue's total three-dimensional volume. A particular feature is that the cells do not have any direct cell-to-cell contact with each other and each cell has to be regarded as an individual functional unit responsible for maintaining the ECM in its immediate surrounding through balanced and tightly regulated anabolic and catabolic activities. The ECM produced by the chondrocytes is specific for hyaline cartilage and 40–50% consists of collagens (90% of which is collagen type II) and 20–25% consists of different proteoglycans (aggrecan, decorin, biglycan and fibromodulin) (Kuettnner, 1992). Cartilage develops during embryogenesis through condensation and subsequent differentiation of MSCs. During this process the cells start to

synthesise cartilage matrix-specific proteoglycans and collagen type II (Cancedda et al., 1995). In adults, articular cartilage chondrocytes retain a mature state; however, in adolescents during enchondral bone development, at the site of the growth plate the chondrocytes become hypertrophic, produce alkaline phosphatase and collagen type X and are eventually reabsorbed while new bone is formed (Cancedda et al., 1995; Kuettnner, 1992). For scientists and medical doctors cartilage repair presents a major challenge because of its unique construction. Cartilage itself lacks both vascularisation and innervation. Healing processes are therefore slow and the resulting scar tissue most often lacks the necessary mechanical properties and physical durability of the original articular cartilage (Cancedda et al., 2003; Vachon et al., 1986). This scar tissue cannot withstand the physiological strain and the result is further degeneration of the cartilage, continued decline in joint function, inflammation, restricted joint movement and deformity. The main symptoms of OA are therefore well known: pain, stiffness and swelling of the joints. Advanced OA leads to further instability, putting stress on the ligaments and tissues surrounding the joints. Currently, more than 200 diseases that affect the joints are summarized under the term OA. Established treatments for OA include mainly preventive measures such as weight control, exercise or treatment of underlying metabolic diseases. Recently, nutraceuticals, which contain polyphenolics, have also been discussed for OA treatment (Csaki et al., 2008; Khanna et al., 2007; Shakibaei et al., 2007a, b). Conservative surgical techniques used to achieve clinical cartilage regeneration (Hunziker, 2002) such as the micro-fracture method (Steadman et al., 1999; Sledge, 2001) and the mosaic-plastic method (Hangody et al., 2001a, b) involve autologous

grafting of chondral or osteochondral fragments. However, the results of trials on OA patients have been unsatisfactory (Quinn et al., 1998a, b; Wohl et al., 1998).

### Cartilage tissue engineering

One of the best-known current regenerative medicine strategies to achieve cartilage defect repair is the Autologous Chondrocyte Transplantation (ACT) method. The ACT method was introduced in the 1980s by a Swedish group as a novel clinical treatment for articular cartilage repair to solve the problem of progressive degeneration in OA joints (Brittberg, 1999). Following the basic principles of repair, a cartilage defect was filled with autologous chondrocytes (i.e. derived from the same patient). The idea was that, by introduction of the chondrocytes in single-cell suspension into the defect, cell condensation would be triggered, imitating the condensation phase in early embryonic development. This condensation phase in turn would provide the chondrocytes with an adequate stimulus to synthesis new cartilage-specific matrix and result in regeneration of articular cartilage tissue in the cartilage defect. In a biopsy a 150–300 mg sample of cartilaginous tissue is removed in an initial surgical procedure from a non-weight-bearing area of the joint, for example in the knee from the supromedial edge of the femoral condyle, and expanded as a cell culture *in vitro* until enough cells are obtained for defect filling. In the second surgical procedure, these cells are then re-implanted into the cartilage defect. To secure the chondrocytes at the implanted side and prevent them from floating away, a periosteal flap is further sewed over the defect (Brittberg et al., 1994, 1996). In several animal studies ACT has shown excellent outcomes (Breinan et al., 1997; Brittberg et al., 1996; Dell'Accio et al., 2003; Grande et al., 1989; Lee et al., 2003; Rahfoth et al., 1998). In human patients ACT has been performed on over 12,000 patients worldwide (Peterson et al., 2000). Results after 3–9 years are very encouraging, with a significant reduction in pain reported in treated patients (Peterson et al., 2002), although repair of the defect is not uniform in all areas of the joint (Brittberg et al., 1994; Peterson et al., 2000).

Although ACT has been in use for some time, it still faces several major challenges, including donor-site morbidity, chondrocyte de-differentiation during *in vitro* culture and fibrocartilage formation after cell implantation instead of defect healing (40% of ACTs show evidence of chondrocytes

hypertrophy) (Dell'Accio et al., 2003; Brittberg et al., 2003; Schulze-Tanzil et al., 2002, 2004b; Brittberg, 1999). Especially, chondrocyte de-differentiation during monolayer culture poses problems. *In vivo*, chondrocytes are embedded in a well-structured ECM, helping them to maintain their function and vitality (Shakibaei et al., 1993, 1997; Shakibaei and Merker, 1999). Monolayer culture, in which chondrocytes are forced to give up their chondrogenic phenotype and the absence of their specific ECM, leads to a shift in the chondrocytes from the production of cartilage-specific proteins, such as collagen type II, to non-specific proteins, such as collagen type I (von der Mark, 1980; von der Mark et al., 1977; Marlovits et al., 2004). After re-implantation these de-differentiated chondrocytes continue to produce unspecific matrix components leading to a more fibrocartilage repair tissue that lacks the biomechanical properties and the resilience of articular cartilage. Up to the fourth passage *in vitro* chondrocytes can spontaneously re-differentiate in a three-dimensional environment (Schulze-Tanzil et al., 2002; Shakibaei et al., 2006). Also, bioactive stimuli such as insulin-like growth factor I (IGF-I) and the transforming growth factor beta (TGF- $\beta$ ) have been shown to prolong and reconstitute the re-differentiation capacity of monolayer-expanded chondrocytes (Barbero et al., 2003; Hunziker, 2001; Jenniskens et al., 2006; Shakibaei et al., 2006).

### Next-generation ACT

As the classical ACT method has shown flaws, refined approaches to promote chondrocyte re-differentiation for effective cartilage repair are on trial, combining chondrocytes with a great variety of carrier systems (scaffolds) or biomaterials (Marlovits et al., 2006). The so-called "second-generation ACT" uses a biomaterial membrane (such as the bilayer collagen type I/type III membrane Chondro-Gide<sup>TM</sup>) instead of the periosteal flap to secure the chondrocytes in the defect. The aim is to reduce a periosteal reaction connected with the periosteal flap usage such as periosteal hypertrophy. In the so-called "third-generation ACT" a three-dimensional environment is created *in vitro* with a scaffold; this is loaded with chondrocytes and this neo-cartilaginous tissue-engineered construct re-implanted. Although materials vary greatly from producer to producer (Hunziker, 2002), in general, scaffold material has to be structurally and mechanically stable, reabsorbable and non-toxic for the cells (Tuli et al., 2003). Some of the most frequently used materials

are polylactide-co-glycolide-based (Mercier et al., 2005), hyaluron-based (Solchaga et al., 2005b) or atelocollagen-based (Ochi et al., 2002). *In vitro* and *in vivo* studies on animals (Wakitani et al., 1998; Solchaga et al., 2005b) and humans (Ochi et al., 2002; Zheng et al., 2007) had quite positive results with up to 75% hyaline cartilage formation after 6 months (Zheng et al., 2007). However, severe signs of hypertrophy and partial ossification of the implants could also be observed (Ochi et al., 2002). As scaffolds may pose additional problems depending on their composition, scaffold-free techniques (Kelm and Fussenegger, 2004; Marlovits et al., 2003) have also been implemented in animal models (Mainil-Varlet et al., 2001; Barnewitz et al., 2003). To enhance tissue integration, several biological substances such as fibrin glue or collagen cross-linkers are on trial, however, up to now without sweeping results (Ahsan et al., 1999; Jurgensen et al., 1997; Grande and Pitman, 1988).

As cartilage lesions are generally large and unconfined and do not provide an appropriate environment for chondrocytes to be retained long enough to elaborate an ECM, problems also remain in second- and third-generation ACT, such as the poor integration of the repair tissue into the surrounding cartilage (Ahsan et al., 1999; Hunziker, 2001, 2002), so that the required size of the neo-cartilaginous construct to fill up the cartilage defect frequently cannot be achieved (Hunziker, 2002) and the loss of the chondrocytes chondrogenic phenotype and re-differentiation potential resulting in chondrocytes being incapable of cartilage production after *in vivo* implantation (Schulze-Tanzil et al., 2002, 2004b; Shakibaei et al., 1999). Therefore, successful repair of cartilage lesions is only likely to be achieved when three-dimensional cartilage implants can be generated that have enough ECM for fixation within the joint.

To achieve this goal a precise knowledge of the biochemical and molecular signaling pathways activated and involved in chondrogenesis is therefore vitally important. A major signaling pathway involved in activation of the chondrogenic differentiation of chondrocytes is the MAPKinase pathway (Schulze-Tanzil et al., 2004b; Shakibaei et al., 2001b), which stimulates the specific chondrogenic transcription factor Sox9. Growth factors such as the insulin like growth factor-I or the transforming growth factor- $\beta$ 1 have been shown to stimulate the MAPKinase pathway through activation of the adaptor protein Shc (Src homology protein) which in turn activates the MAPKinase members ERK 1/2 (extracellular regulated kinase 1/2) (Shakibaei et al., 2006). Monolayer studies have already shown

that *in vitro* stimulation with these growth factors prolongs the chondrocyte re-differentiation potential suggesting that growth factor treatment may indeed be a new approach for ACT (Shakibaei et al., 2006).

## MSCs for cartilage regeneration

As stated above, obtaining vital and differentiated chondrocytes presents one of the major challenges for successful ACT. Not only that each biopsy presents an additional trauma to an already damaged joint cartilage, but the expansion phase the chondrocytes have to undergo *in vitro* leads to rapid cell de-differentiation with a loss of their chondrogenic potential (von der Mark et al., 1977; Darling and Athanasiou, 2005; Shakibaei et al., 1997). Although re-differentiation of these cells has been shown *in vitro* with (Barbero et al., 2003; Jakob et al., 2001) and without (Anderer and Libera, 2002) the addition of growth factors such as TGF- $\beta$ , an alternative, easily obtainable cell source with stable chondrogenic potential becomes necessary. As other cartilage sources such as nasal and rib cartilage have not been fully assessed for their ability to repair articular cartilage (Naumann et al., 2002), an undifferentiated progenitor cell that possesses multilineage differentiation potential and is present everywhere in the body would be ideal for tissue engineering. Here, MSCs present themselves as a promising cell source for the regeneration of cartilage as they possess chondrogenic differentiation potential, are easily obtainable in high numbers and expandable *in vitro* without losing their differentiation potential (Caplan and Goldberg, 1999; Pittenger, 2008).


## Sources, isolation and characterization of MSCs

The term stem cell is used to denote an unspecialized progenitor cell residing in niches in various organs and tissues from which it can be recruited to replenish specific tissue cells when they die (Caplan and Dennis, 2006; Fuchs et al., 2004). Stem cells are not only found in the embryo but also in the fetus and in the adult individual. The acquisition of stem cells for tissue engineering from the fetal or adult individual has the advantage of avoiding possible immunologic responses connected with allogenic cell transplantation. Furthermore, the use of embryonic stem cells presents ethical considerations that are redundant in adult or fetal stem cells. The earliest stem cells to be identified belong to the hematopoietic lineage and were




isolated from the bone marrow. Today, stem cells have been discovered in almost all organs including peripheral blood, bone marrow, muscle, fat, pancreas, skin, neuronal system and others (Till and McCulloch, 1980; Wickham et al., 2003; Zuk et al., 2001; Bottai et al., 2003; Alexanian and Sieber-Blum, 2003; Williams et al., 1999; Caplan, 1991; Cancedda et al., 2003). MSCs have been isolated from bone marrow (Caplan et al., 1997; Friedenstein et al., 1987, 1966), umbilical cord blood (Bieback et al., 2004; Kogler et al., 2004), adipose tissue (Zuk et al., 2002; Kern et al., 2006) and peripheral blood (Huss et al., 2000; Zvaifler et al., 2000; Ukai et al., 2007; Koerner et al., 2006; Giovannini et al., 2008). In the sixties, Friedenstein et al. (1966) had already described the presence, in bone marrow, not only of hematopoietic stem cells but also of MSCs capable of osteogenesis *in vitro*. Today bone-marrow-derived MSCs have been differentiated into various specific cell lineages (Pittenger et al., 1999; Short et al., 2003; Caplan, 1991; Otto and Rao, 2004; Majumdar et al., 2000; Kramer et al., 2004; Conget and Minguell, 1999; Fortier et al., 1998; Carlberg et al., 2001; Csaki et al., 2007). MSCs present approximately 2–3% of the total nuclear cell fraction in the bone marrow. They can easily be isolated through bone marrow aspiration and expanded over several passages without losing their differentiation potential (Caplan, 1991; Csaki et al., 2007; Pittenger et al.,

1999). After obtaining the bone marrow aspirate, for example in humans and canines from the iliac crest or in horses often from the sternum, it should be immediately diluted in 3% citric acid or heparin to prevent blood coagulation. After arrival in the cell-culture laboratory, the stem cells are separated from the remaining bone marrow through density-gradient centrifugation with Ficoll or Percoll (for example from Biochrom, Germany) and plating of the nuclear fraction, through plating the entire bone marrow after erythrolysis, through separating the MSCs by magnetic cell sorting or by FACS analysis (Caplan, 1991; Lange et al., 2005; Lee et al., 2004; Martin et al., 2002). One of the main characteristics of stem cells is their potential to adhere onto plastic during *in vitro* conditions (Figure 2). *In vitro* MSCs have a fibroblast-like morphology which they maintain during extended passaging. Furthermore, they express several adhesion molecules also found on mesenchymal, endothelial and epithelial cells (Conget and Minguell, 1999). The International Society for Cellular Therapy has listed the main factors required for a cell to be regarded as a mesenchymal stem cell in a position statement (Dominici et al., 2006). MSCs are characterized by their adhesion potential in monolayer culture and their differentiation potential into chondrocytes, osteocytes and adipocytes *in vitro* (Figure 3). Furthermore, the International Society for Cellular Therapy has listed




**Figure 2.** Isolation of mesenchymal stem cells from various tissues. Mesenchymal stem cells are routinely isolated and expanded from bone marrow (BM), umbilical cord blood (UCB) and adipose tissue (AT). A cell pellet containing the desired MSCs can be obtained via several isolation methods: (A1) through density-gradient centrifugation and plating of the mononuclear cell fraction, (A2) through plating the entire cell fraction after erythrolysis or cell sorting or (B) through plating the entire cell fraction after enzymatic digestion of the adipose tissue. These isolated cells are then plated at a high density in a culture dish. After a few days single cells adhere. These form colonies (C) and are the mesenchymal stem cells used for the experiments.



**Figure 3.** The multipotency of mesenchymal stem cells. Treatment with an osteogenic-specific induction medium causes the MSCs (A) to differentiate to osteoblasts (B) and deposit mineralized nodules that can be stained with von Kossa. After treatment with a specific adipogenic induction medium, MSCs contain a high amount of neutral lipids (stained with Oil red O), indicating their differentiation into adipocytes (C). In three-dimensional high-density culture, with an appropriate chondrogenic induction medium, MSCs differentiate to chondrocytes (D) and produce cartilage-specific proteoglycans (stained with alcian blue). magnification: (A and B) 200 × ; (C and D) 400 × .

several markers that cells should exhibit or lack in order to be classified as MSCs. Markers that MSCs should exhibit include CD105<sup>+</sup>, CD73<sup>+</sup> and CD90<sup>+</sup>, whereas MSCs should lack CD45<sup>-</sup>, CD34<sup>-</sup> and several other hematopoietic stem cell markers (Csaki et al., 2007; Dominici et al., 2006) (Figure 4). Parallel to bone-marrow-derived MSCs, MSCs are derived from umbilical cord blood. Umbilical cord blood has proven to be a good source of MSCs and umbilical-cord-blood-derived MSCs have been differentiated into multiple cell types such as endothelial cells, neurons, smooth muscle cells, adipocytes, chondroblasts and osteoblasts (Bieback et al., 2004; Kogler et al., 2004; Watt and Contreras, 2005; Aoki et al., 2004). Umbilical-cord-blood-derived MSCs have already become commercially available for horses and humans. Recently it has become increasingly fashionable to encourage parents to have their babies' umbilical cord blood deep frozen in case the need arises for later use. Also, the equine sporting industry has become a fore rider in collecting umbilical cord blood, hoping for regeneration of cartilage and tendon injuries with umbilical-cord-blood-derived MSCs (Koch et al., 2007). Apart from bone marrow and umbilical cord blood, adipose tissue also appears to be a good and plentiful source of MSCs both in humans and

animals (Qu et al., 2007; Yamamoto et al., 2007; Zuk et al., 2001). Adipose-tissue-derived MSCs can be isolated from liposuctions in large numbers and after 1–2 h digestion of the adipose tissue with collagenase in a shaking water bath at 37 °C, easily grown under standard tissue culture conditions (Figure 2). The advantage over other methods of obtaining MSCs is that, for one, adipose tissue can be obtained by procedures that are minimal invasive and, MSCs yields obtained from adipose tissue are higher compared to other sources of MSCs such as bone marrow or umbilical cord blood (Helder et al., 2007; Kern et al., 2006). Although adipose-derived MSCs have been successfully differentiated *in vitro* into different lineage cells including adipogenic, chondrogenic, myogenic and osteogenic cells (Zuk et al., 2002), in the human, adipose-tissue-derived MSCs may have inferior chondropogenitor capacities compared to bone-marrow-derived MSCs (Im et al., 2005). However, in a comparative study of MSCs from bone marrow, adipose tissue and umbilical cord blood no phenotypic differences were observed (Wagner et al., 2005). There have also been reports of MSCs isolated from peripheral blood (Huss et al., 2000; Zvaifler et al., 2000; Ukai et al., 2007; Koerner et al., 2006; Giovannini et al., 2008), although yields are significantly lower and chondrogenic



**Figure 4.** Immunolabeling of isolated mesenchymal stem cells. As defined by the International Society for Cellular Therapy, stem cells should exhibit the markers CD105 and CD90 and should not exhibit the hematopoietic stem cell markers CD45 and CD34. magnification:  $200\times$ .

induction is difficult to achieve. Recently, MSCs were even found to persist in adult cartilage (Alsalameh et al., 2004). Their role is still unclear and the authors of this study argue that fibrocartilage formation during OA might be a result of cytokine-induced wrong programming of cartilage MSCs (Alsalameh et al., 2004).


### Induction of chondrogenesis in MSCs

*In vivo* MSCs differentiation is initiated through an interaction of molecular signals emitted from neighbouring tissue cells that are transduced via either an extra- or intracellular pathway. Differentiation of MSCs can then be induced through stimulation of stem cell surface receptors, soluble cytokine and growth factors, through ECM proteins such as proteoglycans and collagens or through direct interaction with surface proteins of neighbouring cells such as the chondrocytes. Present attempts on *in vitro* chondrogenic differentiation of MSCs are therefore based on the knowledge of chondrogenic development, cartilage homeostasis and function *in vivo*. Chondrogenic differentiation of MSCs *in vitro* is therefore mainly performed in a

three-dimensional environment such as the micro-mass pellet culture as described by Johnstone et al. which is the most frequently used system (Pittenger et al., 1999; Johnstone et al., 1998). Here, 250,000–500,000 MSCs are centrifuged in a conical tube and then incubated for various time periods ranging from 14 to 21 days at  $37^{\circ}\text{C}$  in a humidified atmosphere. After 1 day in culture, the cells aggregate and form a round cell pellet. Other three-dimensional culture methods for cartilage formation include high-density bridge cultures (Figure 5) and alginate bead cultures (Lange et al., 2005; Shakibaei and De Souza, 1997; Shakibaei et al., 1993).

*In vitro* MSCs require a stimulus to differentiate into chondrocytes. This stimulus can be achieved with a large variety of different growth and differentiation factors, hormones or cytokines (Caplan and Goldberg, 1999; Magne et al., 2005). The major ones include TGF- $\beta$ 1, IGF-1, dexamethasone, the family of bone morphogenic proteins (BMPs) and fibroblast growth factor (FGF) (Carlberg et al., 2001; Csaki et al., 2007; Denker et al., 1999; Grigoriadis et al., 1988; Nakayama et al., 2003; Nixon et al., 2000; Pittenger et al., 1999; Tsutsumi et al., 2001).





**Figure 5.** Schematic drawing of the three-dimensional High-Density Culture Model. A nitrocellulose filter is placed on a steel net bridge and cells are cultured on the filter. This model mimics the condensation phase that is at the beginning of cartilage development, by allowing the cells to aggregate and form cell–cell interactions. Cell-culture medium reaches the filter-medium interface, nurturing cells through diffusion, thus mimicking an *in vivo* environment.

In chondrogenic differentiation media, TGF- $\beta$ 1 is the most commonly used growth factor (Caplan, 1991; Pittenger et al., 1999; Johnstone et al., 1998). Chondrogenic differentiation through TGF- $\beta$ 1 is probably mediated by smad3 and  $\beta$ -catenin, as well as along the Wnt signaling pathway, enhancing MSCs proliferation while simultaneously inhibiting adipogenesis and osteogenesis (Zhou et al., 2004; Jian et al., 2006). Up-regulation of  $\beta$ -catenin is essential to commit a cell to the chondrogenic lineage (Day et al., 2005; Hill et al., 2005). However, in mature adult chondrocytes,  $\beta$ -catenin can also stimulate chondrogenic hypertrophy and ossification (Kitagaki et al., 2003; Tamamura et al., 2005). This is a logical step since although articular cartilage chondrocytes normally stay at a mature state, in growing adolescents the chondrocytes become hypertrophic, produce alkaline phosphatase and collagen type X and are then eventually reabsorbed while new bone is formed at the site of the enchondral bone growth plate. TGF- $\beta$ 1 has also been shown to act via the MAPKinase signaling pathway, part of its mechanism being mediated by ERK1/2; however, collagen type II production is independent of this (Longobardi et al., 2006). It is well known that the MAPKinase pathway plays a pivotal role in differentiation, development of the chondrogenic phenotype and specific function of chondrocytes (Shakibaei and Merker, 1999; Shukunami et al., 2001) and recently it was shown that ERK1/2 interacts physically with the chondrogenic transcription factor Sox9 (Shakibaei et al., 2006). This concurs with the findings that inhibition of the MAPKinase pathway

enhances adipogenesis (Jaiswal et al., 2000). IGF-1 can influence chondrogenesis independently of TGF- $\beta$ 1 and may even be involved in a synergism with TGF- $\beta$ 1. Indeed, the expression of the chondrogenic-specific transcription factor Sox9, the amounts of collagen type II and cartilage-specific proteoglycans in MSCs stimulated both with TGF- $\beta$ 1 and IGF-1 were comparable to that of mature adult chondrocytes (Longobardi et al., 2006). Dexamethasone, a synthetic glucocorticoid, stimulates chondrogenesis directly via the glucocorticoid receptor (Derfoul et al., 2006). In animals it has been reported to be a potent stimulant for chondrogenesis in horses, rabbits and bovines (Bosnakovski et al., 2005; Grigoriadis et al., 1988; Johnstone et al., 1998). Interestingly, dexamethasone potentiates the chondrogenic stimulation of TGF- $\beta$  (Derfoul et al., 2006). BMPs, belonging to the TGF- $\beta$  superfamily can further stimulate chondrogenesis (Chubinskaya and Kuettner, 2003; Luyten et al., 1992; Sailor et al., 1996; Schmitt et al., 2003; Knippenberg et al., 2006; Indrawattana et al., 2004). Here especially BMP-7 (Knippenberg et al., 2006), a combination of BMP-2 and TGF- $\beta$  (Schmitt et al., 2003) or a combination of BMP-6 and TGF- $\beta$  (Indrawattana et al., 2004) seem to enhance chondrogenesis whereas BMP-2 alone stimulates osteogenesis (Knippenberg et al., 2006). BMP-2 seems to cooperate, like TGF $\beta$ , with the Wnt signal transduction pathway, up-regulating Wnt3a, leading to accumulation of  $\beta$ -catenin and the subsequent induction of Sox9 and chondrogenesis (Fischer et al., 2002a,b). FGF-2 has also been proposed to stimulate chondrogenesis in MSCs

(Solchaga et al., 2005a; Chiou et al., 2006) and this mechanism of action is mediated via the MAPKinase signaling pathway (Murakami et al., 2000).


### Tissue-engineering cartilage with MSCs

Analogue to the ACT, MSCs have been injected in the knees of animals such as rabbit (Im et al., 2001; Yan and Yu, 2007) and goat (Quintavalla et al., 2002; Murphy et al., 2003). Although combining the MSCs with soluble scaffolds, fibrin glue or a periosteal flap, results have been ambiguous, both formation of new cartilage and degradation and fragmentation of the MSCs has been reported (Im et al., 2001; Yan and Yu, 2007; Murphy et al., 2003; Quintavalla et al., 2002). Further, MSCs have been implanted after *in vitro* differentiation to chondrocytes; however, also here results have been unsatisfactory (Jiang et al., 2003). The approach of loading MSCs onto a three-dimensional scaffold *in vitro* could provide a three-dimensional construct with mechanical properties that are congruent with the weight-bearing function of the joint (Noth et al., 2008). Therefore, MSCs have been implanted on scaffolds and indeed successful formation of cartilage-like tissue was observed in parts of the defect (Chen et al., 2005; Wakitani et al., 1994; Meinel et al., 2004; Liu et al., 2006).

Attempts have been made such as press-coating MSCs onto the surface of a bio-degradable polymer or seeding the MSCs onto an amalgam scaffold of poly-L-lactic acid and alginate (Cateron et al., 2002, 2001). Recently, electrospun nanofiber scaffolds have come into focus of cartilage tissue engineering with MSCs (Li et al., 2002, 2005a, b; Yoshimoto et al., 2003).

### Cartilage repair in clinical trials

To achieve clinical effectiveness, safety and practicality of using MSCs for cartilage repair will be necessary (Xian and Foster, 2006). As treatment of animals with MSCs has led to ambiguous results, clinical trials on human patients using MSCs for articular cartilage repair are scarce (Wakitani, 2007; Wakitani et al., 2002). Wakitani et al. (2002) performed a study on 24 human patients. In this study, autologous MSCs were obtained from the patients' bone marrow, expanded in monolayer culture, seeded onto a collagen type I membrane and transplanted into the cartilage defect. Twelve patients served as the control group and received cell-free implants. The 2-year outcome showed significantly greater hyaline cartilage formation in the treated compared to the untreated group. However, there was no way of tracking the



**Figure 6.** Transmission electron microscopy: High-Density Culture. Chondrogenic-induced MSCs differentiate into chondrocytes (C) and demonstrate typical cartilage nodule formation with deposition of cartilage-specific extracellular matrix (ECM) in high-density culture conditions. Cartilage nodules are surrounded by a layer of flattened fibroblast-like MSCs, resembling a perichondrium-like structure (P). During appositional growth of the cartilage nodule, MSCs are recruited from this outer layer. This transitional zone is shown in the picture: MSCs with a flattened fibroblast morphology and large, thick fibrillar ECM production differentiate into smaller, rounded chondrocytes and produce fine-structured ECM. Magnification: 6500  $\times$ ; Inset: immunolabeling demonstration of collagen type II after 7 days in culture. Collagen fibrils are present and gold particles are detectable only on collagenous fibrils in the cartilage matrix (arrows). Magnification: 75,000  $\times$ .

implanted MSCs for this long time period, so it remains unclear whether the newly formed tissue consisted of the implanted MSCs.

### Hurdles in tissue-engineering cartilage from MSCs

A major hurdle in cartilage tissue engineering with MSCs is inadequate aging of the tissue-engineered constructs. During *in vitro* chondrogenesis, MSCs not only up-regulate hyaline cartilage-specific markers such as collagen type II (Figure 6) and adequate cartilage-specific proteins such as aggrecan, but also markers typical for hypertrophic chondrocytes such as collagen type X and alkaline phosphatase (Johnstone et al., 1998). Collagen type X makes up 45% of the collagen produced in hypertrophic chondrocytes and is therefore considered an important marker of enchondral bone formation (Shen, 2005; Gibson and Flint, 1985). In chondrogenic differentiated MSCs, collagen type X is considerably up-regulated in three-dimensional culture and detectable around day 7 with RT-PCR (Johnstone et al., 1998; Barry et al., 2001) and around day 14 with immunohistochemistry (Nishio-ka et al., 2005; Yoo et al., 1998). In contrast, in healthy mature chondrocytes and in engineered cartilage from mature chondrocytes, collagen type X is not or is only marginally expressed (Zhang et al., 2004; Riesle et al., 1998; Tallheden et al., 2004).

Alkaline phosphatase activity, generally regarded as a typical marker for osteogenesis can also be found in large amounts in hypertrophic chondrocytes in the calcified zone, in enchondral ossification centers and the growth plate (Henson et al., 1995; Miao and Scutt, 2002). During chondrogenic induction, MSCs upregulate alkaline phosphatase production around the 7th day, reaching a peak around the 14th day (Johnstone et al., 1998). In contrast to MSCs, in adult mature chondrocytes from the superficial and the middle zone of the joint surface, Alkaline phosphatase activity is minimal (Henson et al., 1995; Miao and Scutt, 2002).

### Conclusion

In conclusion, MSCs present themselves as promising, attractive tools for cartilage repair. Their properties make them ideal to study the development, physiology and disease of cartilage. MSCs can be obtained rather easily from a great number of tissues of which the most suitable seem to be bone

marrow, umbilical cord blood and adipose tissue. One of their great advantages, in contrast to chondrocytes, is that they have a high proliferative potential in culture and can be expanded to obtain enough cells for tissue engineering of cartilage. Today, tissue engineering and stem cell technologies have established themselves as approved new approaches especially in cartilage and OA research. However, although research with MSCs for cartilage and connective tissue repair has come a long way, we are still only at the beginning of this exciting new journey. Future studies will need to investigate mechanisms of MSC differentiation and the biochemical signal transduction pathways involved in maintaining and enhancing chondrogenic differentiation in even more detail. Understanding the biology of MSCs and their interaction with three-dimensional scaffolds will enable us to create more appropriate biomaterials capable of replacing cartilage defects and eventually make our dream of forming "laboratory-made" connective tissues including cartilage, bone and tendon come true.

### Acknowledgements

The authors are grateful to Mrs. Karoline Fischer for her excellent technical assistance and to Mrs. Simone Nebrich for her additional support. This work was supported in part by the Friedrich Bauer Stiftung, Munich, Germany.

### References

- Ahmed, I.M., Lagopoulos, M., McConnell, P., Soames, R.W., Sefton, G.K., 1998. Blood supply of the Achilles tendon. *J. Orthop. Res.* 16, 591–596.
- Ahsan, T., Lottman, L.M., Harwood, F., Amiel, D., Sah, R.L., 1999. Integrative cartilage repair: inhibition by beta-aminopropionitrile. *J. Orthop. Res.* 17, 850–857.
- Alexanian, A.R., Sieber-Blum, M., 2003. Differentiating adult hippocampal stem cells into neural crest derivatives. *Neuroscience* 118, 1–5.
- Alsalameh, S., Amin, R., Gemba, T., Lotz, M., 2004. Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. *Arthritis Rheum.* 50, 1522–1532.
- Anderer, U., Libera, J., 2002. *In vitro* engineering of human autogenous cartilage. *J. Bone Miner. Res.* 17, 1420–1429.
- Aoki, M., Yasutake, M., Murohara, T., 2004. Derivation of functional endothelial progenitor cells from human umbilical cord blood mononuclear cells isolated by a novel cell filtration device. *Stem cells* 22, 994–1002.
- Barbero, A., Ploegert, S., Heberer, M., Martin, I., 2003. Plasticity of clonal populations of dedifferentiated

- adult human articular chondrocytes. *Arthritis Rheum.* 48, 1315–1325.
- Barnewitz, D., Evers, A., Zimmermann, J., Wilke, I., Kaps, C., Sittinger, M., 2003. Tissue engineering: new treatment of cartilage alterations in degenerative joint diseases in horses – preliminary results of a long term study. *Berl. Munch. Tierarztl. Wochenschr.* 116, 157–161.
- Barry, F., Boynton, R.E., Liu, B., Murphy, J.M., 2001. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. *Exp. Cell Res.* 268, 189–200.
- Beris, A.E., Lykissas, M.G., Papageorgiou, C.D., Georgoulis, A.D., 2005. Advances in articular cartilage repair. *Injury* 36 (Suppl. 4), S14–S23.
- Bieback, K., Kern, S., Kluter, H., Eichler, H., 2004. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. *Stem cells* 22, 625–634.
- Bosch, U., 2000. Tendon injuries: on the threshold of a new era. *Orthopade* 29, 173.
- Bosnakovski, D., Mizuno, M., Kim, G., Takagi, S., Okumura, M., Fujinaga, T., 2005. Isolation and multilineage differentiation of bovine bone marrow mesenchymal stem cells. *Cell Tissue Res.* 319, 243–253.
- Bottai, D., Fiocco, R., Gelain, F., Deflippis, L., Galli, R., Gritti, A., Vescevi, L.A., 2003. Neural stem cells in the adult nervous system. *J. Hematother. Stem Cell Res.* 12, 655–670.
- Breinan, H.A., Minas, T., Hsu, H.P., Nehrer, S., Sledge, C.B., Spector, M., 1997. Effect of cultured autologous chondrocytes on repair of chondral defects in a canine model. *J. Bone Joint Surg. Am.* 79, 1439–1451.
- Brittberg, M., 1999. Autologous chondrocyte transplantation. *Clin. Orthop. Relat. Res.* 367 (Suppl.), S147–S155.
- Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., Peterson, L., 1994. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N. Engl. J. Med.* 331, 889–895.
- Brittberg, M., Nilsson, A., Lindahl, A., Ohlsson, C., Peterson, L., 1996. Rabbit articular cartilage defects treated with autologous cultured chondrocytes. *Clin. Orthop. Relat. Res.* 326, 270–283.
- Brittberg, M., Peterson, L., Sjogren-Jansson, E., Tallheden, T., Lindahl, A., 2003. Articular cartilage engineering with autologous chondrocyte transplantation. A review of recent developments. *J. Bone Joint. Surg. Am.* 85-A (Suppl. 3), 109–115.
- Cancedda, R., Descalzi Cancedda, F., Castagnola, P., 1995. Chondrocyte differentiation. *Int. Rev. Cytol.* 159, 265–358.
- Cancedda, R., Dozin, B., Giannoni, P., Quarto, R., 2003. Tissue engineering and cell therapy of cartilage and bone. *Matrix Biol.* 22, 81–91.
- Canty, E.G., Kadler, K.E., 2002. Collagen fibril biosynthesis in tendon: a review and recent insights. *Comp. Biochem. Physiol. A Mol. Integr. Physiol.* 133, 979–985.
- Caplan, A.I., 1991. Mesenchymal stem cells. *J. Orthop. Res.* 9, 641–650.
- Caplan, A.I., 2000. Tissue engineering designs for the future: new logics, old molecules. *Tissue Eng.* 6, 1–8.
- Caplan, A.I., Dennis, J.E., 2006. Mesenchymal stem cells as trophic mediators. *J. Cell Biochem.* 98, 1076–1084.
- Caplan, A.I., Goldberg, V.M., 1999. Principles of tissue engineered regeneration of skeletal tissues. *Clin. Orthop. Relat. Res.* 367 (Suppl.), S12–S16.
- Caplan, A.I., Elyaderani, M., Mochizuki, Y., Wakitani, S., Goldberg, V.M., 1997. Principles of cartilage repair and regeneration. *Clin. Orthop. Relat. Res.* 342, 254–269.
- Carlberg, A.L., Pucci, B., Rallapalli, R., Tuan, R.S., Hall, D.J., 2001. Efficient chondrogenic differentiation of mesenchymal cells in micromass culture by retroviral gene transfer of BMP-2. *Differentiation* 67, 128–138.
- Caterson, E.J., Nesti, L.J., Li, W.J., Danielson, K.G., Albert, T.J., Vaccaro, A.R., Tuan, R.S., 2001. Three-dimensional cartilage formation by bone marrow-derived cells seeded in polylactide/alginate amalgam. *J. Biomed. Mater. Res.* 57, 394–403.
- Caterson, E.J., Li, W.J., Nesti, L.J., Albert, T., Danielson, K., Tuan, R.S., 2002. Polymer/alginate amalgam for cartilage–tissue engineering. *Ann. NY Acad. Sci.* 961, 134–138.
- Chen, J., Wang, C., Lu, S., Wu, J., Guo, X., Duan, C., Dong, L., Song, Y., Zhang, J., Jing, D., Wu, L., Ding, J., Li, D., 2005. In vivo chondrogenesis of adult bone-marrow-derived autologous mesenchymal stem cells. *Cell Tissue Res.* 319, 429–438.
- Chiou, M., Xu, Y., Longaker, M.T., 2006. Mitogenic and chondrogenic effects of fibroblast growth factor-2 in adipose-derived mesenchymal cells. *Biochem. Biophys. Res. Commun.* 343, 644–652.
- Chubinskaya, S., Kuettner, K.E., 2003. Regulation of osteogenic proteins by chondrocytes. *Int. J. Biochem. Cell Biol.* 35, 1323–1340.
- Conget, P.A., Minguell, J.J., 1999. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. *J. Cell Physiol.* 181, 67–73.
- Csaki, C., Matis, U., Mobasheri, A., Ye, H., Shakibaei, M., 2007. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. *Histochem. Cell Biol.* 128, 507–520.
- Csaki, C., Keshishzadeh, N., Fischer, K., Shakibaei, M., 2008. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. *Biochem. Pharmacol.* 75, 677–687.
- Czitrom, A.A., Langer, F., McKee, N., Gross, A.E., 1986. Bone and cartilage allotransplantation. A review of 14 years of research and clinical studies. *Clin. Orthop. Relat. Res.* 208, 141–145.
- Darling, E.M., Athanasiou, K.A., 2005. Rapid phenotypic changes in passaged articular chondrocyte subpopulations. *J. Orthop. Res.* 23, 425–432.
- Day, T.F., Guo, X., Garrett-Beal, L., Yang, Y., 2005. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation



- during vertebrate skeletogenesis. *Dev. Cell* 8, 739–750.
- Dell'Accio, F., Vanlauwe, J., Bellemans, J., Neys, J., De Bari, C., Luyten, F.P., 2003. Expanded phenotypically stable chondrocytes persist in the repair tissue and contribute to cartilage matrix formation and structural integration in a goat model of autologous chondrocyte implantation. *J. Orthop. Res.* 21, 123–131.
- Denker, A.E., Haas, A.R., Nicoll, S.B., Tuan, R.S., 1999. Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micro-mass cultures. *Differentiation* 64, 67–76.
- Derfoul, A., Perkins, G.L., Hall, D.J., Tuan, R.S., 2006. Glucocorticoids promote chondrogenic differentiation of adult human mesenchymal stem cells by enhancing expression of cartilage extracellular matrix genes. *Stem cells* 24, 1487–1495.
- Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., Horwitz, E., 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8, 315–317.
- Fischer, L., Boland, G., Tuan, R.S., 2002a. Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells. *J. Biol. Chem.* 277, 30870–30878.
- Fischer, L., Boland, G., Tuan, R.S., 2002b. Wnt signaling during BMP-2 stimulation of mesenchymal chondrogenesis. *J. Cell Biochem.* 84, 816–831.
- Fortier, L.A., Nixon, A.J., Williams, J., Cable, C.S., 1998. Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells. *Am. J. Vet. Res.* 59, 1182–1187.
- Friedenstein, A.J., Piatetzky II, S., Petrakova, K.V., 1966. Osteogenesis in transplants of bone marrow cells. *J. Embryol. Exp. Morphol.* 16, 381–390.
- Friedenstein, A.J., Chailakhyan, R.K., Gerasimov, U.V., 1987. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. *Cell Tissue Kinet.* 20, 263–272.
- Fuchs, E., Tumber, T., Guasch, G., 2004. Socializing with the neighbors: stem cells and their niche. *Cell* 116, 769–778.
- Gibson, G.J., Flint, M.H., 1985. Type X collagen synthesis by chick sternal cartilage and its relationship to endochondral development. *J. Cell Biol.* 101, 277–284.
- Giovannini, S., Brehm, W., Mainil-Varlet, P., Nestic, D., 2008. Multilineage differentiation potential of equine blood-derived fibroblast-like cells. *Differentiation* 76, 118–129.
- Grande, D.A., Pitman, M.I., 1988. The use of adhesives in chondrocyte transplantation surgery. Preliminary studies. *Bull. Hosp. Joint Dis. Orthop. Inst.* 48, 140–148.
- Grande, D.A., Pitman, M.I., Peterson, L., Menche, D., Klein, M., 1989. The repair of experimentally produced defects in rabbit articular cartilage by autologous chondrocyte transplantation. *J. Orthop. Res.* 7, 208–218.
- Grigoriadis, A.E., Heersche, J.N., Aubin, J.E., 1988. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. *J. Cell Biol.* 106, 2139–2151.
- Hangody, L., Fules, P., 2003. Autologous osteochondral mosaicplasty for the treatment of full-thickness defects of weight-bearing joints: ten years of experimental and clinical experience. *J. Bone Joint Surg. Am.* 85-A (Suppl. 2), 25–32.
- Hangody, L., Feczko, P., Bartha, L., Bodo, G., Kish, G., 2001a. Mosaicplasty for the treatment of articular defects of the knee and ankle. *Clin. Orthop. Relat. Res.* 391 (Suppl.), S328–S336.
- Hangody, L., Kish, G., Modis, L., Szerb, I., Gaspar, L., Dioszegi, Z., Kendik, Z., 2001b. Mosaicplasty for the treatment of osteochondritis dissecans of the talus: two to seven year results in 36 patients. *Foot Ankle Int.* 22, 552–558.
- Hankemeier, S., van Griensven, M., Ezechieli, M., Barkhausen, T., Austin, M., Jagodzinski, M., Meller, R., Bosch, U., Krettek, C., Zeichen, J., 2007. Tissue engineering of tendons and ligaments by human bone marrow stromal cells in a liquid fibrin matrix in immunodeficient rats: results of a histologic study. *Arch. Orthop. Trauma. Surg.* 127, 815–821.
- Helder, M.N., Knippenberg, M., Klein-Nulend, J., Wuisman, P.I., 2007. Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. *Tissue Eng.* 13, 1799–1808.
- Henson, F.M., Davies, M.E., Skepper, J.N., Jeffcott, L.B., 1995. Localisation of alkaline phosphatase in equine growth cartilage. *J. Anat.* 187, 151–159.
- Hill, T.P., Spater, D., Taketo, M.M., Birchmeier, W., Hartmann, C., 2005. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. *Dev. Cell* 8, 727–738.
- Hollander, A.P., Dickinson, S.C., Sims, T.J., Brun, P., Cortivo, R., Kon, E., Marcacci, M., Zanasi, S., Borriore, A., De Luca, C., Pavesio, A., Soranzo, C., Abatangelo, G., 2006. Maturation of tissue engineered cartilage implanted in injured and osteoarthritic human knees. *Tissue Eng.* 12, 1787–1798.
- Hunziker, E.B., 2001. Growth-factor-induced healing of partial-thickness defects in adult articular cartilage. *Osteoarthritis Cartilage* 9, 22–32.
- Hunziker, E.B., 2002. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. *Osteoarthritis Cartilage* 10, 432–463.
- Huss, R., Lange, C., Weissinger, E.M., Kolb, H.J., Thalmeier, K., 2000. Evidence of peripheral blood-derived, plastic-adherent CD34(-/low) hematopoietic stem cell clones with mesenchymal stem cell characteristics. *Stem cells* 18, 252–260.
- Im, G.I., Kim, D.Y., Shin, J.H., Hyun, C.W., Cho, W.H., 2001. Repair of cartilage defect in the rabbit with



- cultured mesenchymal stem cells from bone marrow. *J. Bone Joint Surg. Br.* 83, 289–294.
- Im, G.I., Shin, Y.W., Lee, K.B., 2005. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells? *Osteoarthritis Cartilage* 13, 845–853.
- Indrawattana, N., Chen, G., Tadokoro, M., Shann, L.H., Ohgushi, H., Tateishi, T., Tanaka, J., Bunyaratvej, A., 2004. Growth factor combination for chondrogenic induction from human mesenchymal stem cell. *Biochem. Biophys. Res. Commun.* 320, 914–919.
- Jaiswal, R.K., Jaiswal, N., Bruder, S.P., Mbalaviele, G., Marshak, D.R., Pittenger, M.F., 2000. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. *J. Biol. Chem.* 275, 9645–9652.
- Jakob, M., Demartean, O., Schafer, D., Hintermann, B., Dick, W., Heberer, M., Martin, I., 2001. Specific growth factors during the expansion and redifferentiation of adult human articular chondrocytes enhance chondrogenesis and cartilaginous tissue formation in vitro. *J. Cell Biochem.* 81, 368–377.
- Jenniskens, Y.M., Koevoet, W., de Bart, A.C., Weinans, H., Jahr, H., Verhaar, J.A., DeGroot, J., van Osch, G.J., 2006. Biochemical and functional modulation of the cartilage collagen network by IGF1, TGFbeta2 and FGF2. *Osteoarthritis Cartilage* 14, 1136–1146.
- Jian, H., Shen, X., Liu, I., Semenov, M., He, X., Wang, X.F., 2006. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. *Genes Dev.* 20, 666–674.
- Jiang, X., Cui, P.C., Chen, W.X., Zhang, Z.P., 2003. In vivo chondrogenesis of induced human marrow mesenchymal stem cells in nude mice. *Di Yi Jun Yi Da Xue Xue Bao* 23, 766–769, 773.
- Johnstone, B., Hering, T.M., Caplan, A.I., Goldberg, V.M., Yoo, J.U., 1998. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp. Cell Res.* 238, 265–272.
- Jurgensen, K., Aeschlimann, D., Cavin, V., Genge, M., Hunziker, E.B., 1997. A new biological glue for cartilage–cartilage interfaces: tissue transglutaminase. *J. Bone. Joint. Surg. Am.* 79, 185–193.
- Kajiwara, R., Ishida, O., Kawasaki, K., Adachi, N., Yasunaga, Y., Ochi, M., 2005. Effective repair of a fresh osteochondral defect in the rabbit knee joint by articulated joint distraction following subchondral drilling. *J. Orthop. Res.* 23, 909–915.
- Kannus, P., 2000. Structure of the tendon connective tissue. *Scand. J. Med. Sci. Sports* 10, 312–320.
- Kelm, J.M., Fussenegger, M., 2004. Microscale tissue engineering using gravity-enforced cell assembly. *Trends Biotechnol.* 22, 195–202.
- Kern, S., Eichler, H., Stoeve, J., Kluter, H., Bieback, K., 2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem cells* 24, 1294–1301.
- Khanna, D., Sethi, G., Ahn, K.S., Pandey, M.K., Kunnumakkara, A.B., Sung, B., Aggarwal, A., Aggarwal, B.B., 2007. Natural products as a gold mine for arthritis treatment. *Curr. Opin. Pharmacol.* 7, 344–351.
- Kitagaki, J., Iwamoto, M., Liu, J.G., Tamamura, Y., Pacifici, M., Enomoto-Iwamoto, M., 2003. Activation of beta-catenin-LEF/TCF signal pathway in chondrocytes stimulates ectopic endochondral ossification. *Osteoarthritis Cartilage* 11, 36–43.
- Knippenberg, M., Helder, M.N., Zandieh Doulabi, B., Wuisman, P.I., Klein-Nulend, J., 2006. Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells. *Biochem. Biophys. Res. Commun.* 342, 902–908.
- Koch, T.G., Heerens, T., Thomsen, P.D., Betts, D.H., 2007. Isolation of mesenchymal stem cells from equine umbilical cord blood. *BMC Biotechnol.* 7, 26.
- Koerner, J., Nesic, D., Romero, J.D., Brehm, W., Mainil-Varlet, P., Grogan, S.P., 2006. Equine peripheral blood-derived progenitors in comparison to bone marrow-derived mesenchymal stem cells. *Stem cells* 24, 1613–1619.
- Kogler, G., Sensken, S., Airey, J.A., Trapp, T., Muschen, M., Feldhahn, N., Liedtke, S., Sorg, R.V., Fischer, J., Rosenbaum, C., Greschat, S., Knipper, A., Bender, J., Degistirici, O., Gao, J., Caplan, A.I., Colletti, E.J., Almeida-Porada, G., Muller, H.W., Zanjani, E., Wernet, P., 2004. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. *J. Exp. Med.* 200, 123–135.
- Kramer, P.R., Nares, S., Kramer, S.F., Grogan, D., Kaiser, M., 2004. Mesenchymal stem cells acquire characteristics of cells in the periodontal ligament in vitro. *J. Dent. Res.* 83, 27–34.
- Krampera, M., Pizzolo, G., Aprili, G., Franchini, M., 2006. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. *Bone* 39, 678–683.
- Kuettner, K.E., 1992. Biochemistry of articular cartilage in health and disease. *Clin. Biochem.* 25, 155–163.
- Kuo, C.K., Li, W.J., Mauck, R.L., Tuan, R.S., 2006. Cartilage tissue engineering: its potential and uses. *Curr. Opin. Rheumatol.* 18, 64–73.
- Lange, C., Schroeder, J., Stute, N., Lioznov, M.V., Zander, A.R., 2005. High-potential human mesenchymal stem cells. *Stem Cells Dev.* 14, 70–80.
- Lee, C.R., Grodzinsky, A.J., Hsu, H.P., Spector, M., 2003. Effects of a cultured autologous chondrocyte-seeded type II collagen scaffold on the healing of a chondral defect in a canine model. *J. Orthop. Res.* 21, 272–281.
- Lee, R.H., Kim, B., Choi, I., Kim, H., Choi, H.S., Suh, K., Bae, Y.C., Jung, J.S., 2004. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. *Cell Physiol. Biochem.* 14, 311–324.
- Li, W.J., Laurencin, C.T., Caterson, E.J., Tuan, R.S., Ko, F.K., 2002. Electrospun nanofibrous structure: a novel scaffold for tissue engineering. *J. Biomed. Mater. Res.* 60, 613–621.

- Li, W.J., Tuli, R., Huang, X., Laquerriere, P., Tuan, R.S., 2005a. Multilineage differentiation of human mesenchymal stem cells in a three-dimensional nanofibrous scaffold. *Biomaterials* 26, 5158–5166.
- Li, W.J., Tuli, R., Okafor, C., Derfoul, A., Danielson, K.G., Hall, D.J., Tuan, R.S., 2005b. A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. *Biomaterials* 26, 599–609.
- Liu, Y., Shu, X.Z., Prestwich, G.D., 2006. Osteochondral defect repair with autologous bone marrow-derived mesenchymal stem cells in an injectable, in situ, cross-linked synthetic extracellular matrix. *Tissue Eng.* 12, 3405–3416.
- Longobardi, L., O'Rear, L., Aakula, S., Johnstone, B., Shimer, K., Chytil, A., Horton, W.A., Moses, H.L., Spagnoli, A., 2006. Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling. *J. Bone Miner. Res.* 21, 626–636.
- Luyten, F.P., Yu, Y.M., Yanagishita, M., Vukicevic, S., Hammonds, R.G., Reddi, A.H., 1992. Natural bovine osteogenin and recombinant human bone morphogenetic protein-2B are equipotent in the maintenance of proteoglycans in bovine articular cartilage explant cultures. *J. Biol. Chem.* 267, 3691–3695.
- Magne, D., Vinatier, C., Julien, M., Weiss, P., Guicheux, J., 2005. Mesenchymal stem cell therapy to rebuild cartilage. *Trends Mol. Med.* 11, 519–526.
- Mainil-Varlet, P., Rieser, F., Grogan, S., Mueller, W., Saager, C., Jakob, R.P., 2001. Articular cartilage repair using a tissue-engineered cartilage-like implant: an animal study. *Osteoarthritis Cartilage* 9 (Suppl. A), S6–S15.
- Majumdar, M., B, V, Peluso, D.P., Morris, E.A., 2000. Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. *J. Cell Physiol.* 185, 98–106.
- Marco, F., Lopez-Oliva, F., Fernandez Fernandez-Arroyo, J.M., de Pedro, J.A., Perez, A.J., Leon, C., Lopez-Duran, L., 1993. Osteochondral allografts for osteochondritis dissecans and osteonecrosis of the femoral condyles. *Int. Orthop.* 17, 104–108.
- Marlovits, S., Tichy, B., Truppe, M., Gruber, D., Vecsei, V., 2003. Chondrogenesis of aged human articular cartilage in a scaffold-free bioreactor. *Tissue Eng.* 9, 1215–1226.
- Marlovits, S., Hombauer, M., Truppe, M., Vecsei, V., Schlegel, W., 2004. Changes in the ratio of type-I and type-II collagen expression during monolayer culture of human chondrocytes. *J. Bone Joint. Surg. Br.* 86, 286–295.
- Marlovits, S., Zeller, P., Singer, P., Resinger, C., Vecsei, V., 2006. Cartilage repair: generations of autologous chondrocyte transplantation. *Eur. J. Radiol.* 57, 24–31.
- Martin, D.R., Cox, N.R., Hathcock, T.L., Niemeyer, G.P., Baker, H.J., 2002. Isolation and characterization of multipotential mesenchymal stem cells from feline bone marrow. *Exp. Hematol.* 30, 879–886.
- Meinel, L., Hofmann, S., Karageorgiou, V., Zichner, L., Langer, R., Kaplan, D., Vunjak-Novakovic, G., 2004. Engineering cartilage-like tissue using human mesenchymal stem cells and silk protein scaffolds. *Biotechnol. Bioeng.* 88, 379–391.
- Mercier, N.R., Costantino, H.R., Tracy, M.A., Bonassar, L.J., 2005. Poly(lactide-co-glycolide) microspheres as a moldable scaffold for cartilage tissue engineering. *Biomaterials* 26, 1945–1952.
- Meyers, M.H., Jones, R.E., Bucholz, R.W., Wenger, D.R., 1983. Fresh autogenous grafts and osteochondral allografts for the treatment of segmental collapse in osteonecrosis of the hip. *Clin. Orthop. Relat. Res.* 174, 107–112.
- Miao, D., Scutt, A., 2002. Histochemical localization of alkaline phosphatase activity in decalcified bone and cartilage. *J. Histochem. Cytochem.* 50, 333–340.
- Moller, H.D., Evans, C.H., Maffulli, N., 2000. Current aspects of tendon healing. *Orthopade* 29, 182–187.
- Murakami, S., Kan, M., McKeenan, W.L., de Crombrughe, B., 2000. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. *Proc. Natl. Acad. Sci. USA* 97, 1113–1118.
- Murphy, J.M., Fink, D.J., Hunziker, E.B., Barry, F.P., 2003. Stem cell therapy in a caprine model of osteoarthritis. *Arthritis Rheum.* 48, 3464–3474.
- Nakayama, N., Duryea, D., Manoukian, R., Chow, G., Han, C.Y., 2003. Macroscopic cartilage formation with embryonic stem-cell-derived mesodermal progenitor cells. *J. Cell Sci.* 116, 2015–2028.
- Naumann, A., Dennis, J.E., Awadallah, A., Carrino, D.A., Mansour, J.M., Kastenbauer, E., Caplan, A.I., 2002. Immunochemical and mechanical characterization of cartilage subtypes in rabbit. *J. Histochem. Cytochem.* 50, 1049–1058.
- Nishioka, K., Dennis, J.E., Gao, J., Goldberg, V.M., Caplan, A.I., 2005. Sustained Wnt protein expression in chondral constructs from mesenchymal stem cells. *J. Cell Physiol.* 203, 6–14.
- Nixon, A.J., Brower-Toland, B.D., Bent, S.J., Saxer, R.A., Wilke, M.J., Robbins, P.D., Evans, C.H., 2000. Insulin like growth factor-I gene therapy applications for cartilage repair. *Clin. Orthop. Relat. Res.* 379 (Suppl.), S201–S213.
- Noth, U., Steinert, A.F., Tuan, R.S., 2008. Technology Insight: adult mesenchymal stem cells for osteoarthritis therapy. *Nat. Clin. Pract. Rheumatol.* 4, 371–380.
- Ochi, M., Uchio, Y., Kawasaki, K., Wakitani, S., Iwasa, J., 2002. Transplantation of cartilage-like tissue made by tissue engineering in the treatment of cartilage defects of the knee. *J. Bone Joint. Surg. Br.* 84, 571–578.
- Otto, W.R., Rao, J., 2004. Tomorrow's skeleton staff: mesenchymal stem cells and the repair of bone and cartilage. *Cell Prolif.* 37, 97–110.
- Peterson, L., Minas, T., Brittberg, M., Nilsson, A., Sjogren-Jansson, E., Lindahl, A., 2000. Two- to 9-year outcome after autologous chondrocyte

- transplantation of the knee. *Clin. Orthop. Relat. Res.* 374, 212–234.
- Peterson, L., Brittberg, M., Kiviranta, I., Akerlund, E.L., Lindahl, A., 2002. Autologous chondrocyte transplantation. Biomechanics and long-term durability. *Am. J. Sports Med.* 30, 2–12.
- Pittenger, M.F., 2008. Mesenchymal stem cells from adult bone marrow. *Methods Mol. Biol.* 449, 27–44.
- Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., Marshak, D.R., 1999. Multilineage potential of adult human mesenchymal stem cells. *Science* 284, 143–147.
- Qu, C.Q., Zhang, G.H., Zhang, L.J., Yang, G.S., 2007. Osteogenic and adipogenic potential of porcine adipose mesenchymal stem cells. *In Vitro Cell Dev. Biol. Anim.* 43, 95–100.
- Quinn, T.M., Grodzinsky, A.J., Buschmann, M.D., Kim, Y.J., Hunziker, E.B., 1998a. Mechanical compression alters proteoglycan deposition and matrix deformation around individual cells in cartilage explants. *J. Cell Sci.* 111, 573–583.
- Quinn, T.M., Grodzinsky, A.J., Hunziker, E.B., Sandy, J.D., 1998b. Effects of injurious compression on matrix turnover around individual cells in calf articular cartilage explants. *J. Orthop. Res.* 16, 490–499.
- Quintavalla, J., Uziel-Fusi, S., Yin, J., Boehnlein, E., Pastor, G., Blancuzzi, V., Singh, H.N., Kraus, K.H., O'Byrne, E., Pellas, T.C., 2002. Fluorescently labeled mesenchymal stem cells (MSCs) maintain multilineage potential and can be detected following implantation into articular cartilage defects. *Biomaterials* 23, 109–119.
- Rahfoth, B., Weisser, J., Sternkopf, F., Aigner, T., von der Mark, K., Brauer, R., 1998. Transplantation of allograft chondrocytes embedded in agarose gel into cartilage defects of rabbits. *Osteoarthritis Cartilage* 6, 50–65.
- Rees, S.G., Flannery, C.R., Little, C.B., Hughes, C.E., Caterson, B., Dent, C.M., 2000. Catabolism of aggrecan, decorin and biglycan in tendon. *Biochem. J.* 350, 181–188.
- Riesle, J., Hollander, A.P., Langer, R., Freed, L.E., Vunjak-Novakovic, G., 1998. Collagen in tissue-engineered cartilage: types, structure, and crosslinks. *J. Cell Biochem.* 71, 313–327.
- Sailor, L.Z., Hewick, R.M., Morris, E.A., 1996. Recombinant human bone morphogenetic protein-2 maintains the articular chondrocyte phenotype in long-term culture. *J. Orthop. Res.* 14, 937–945.
- Schmitt, B., Ringe, J., Haupl, T., Notter, M., Manz, R., Burmester, G.R., Sittinger, M., Kaps, C., 2003. BMP2 initiates chondrogenic lineage development of adult human mesenchymal stem cells in high-density culture. *Differentiation* 71, 567–577.
- Schulze-Tanzil, G., de Souza, P., Villegas Castrejon, H., John, T., Merker, H.J., Scheid, A., Shakibaei, M., 2002. Redifferentiation of dedifferentiated human chondrocytes in high-density cultures. *Cell Tissue Res.* 308, 371–379.
- Schulze-Tanzil, G., Mobasheri, A., Clegg, P.D., Sendzik, J., John, T., Shakibaei, M., 2004a. Cultivation of human tenocytes in high-density culture. *Histochem. Cell Biol.* 122, 219–228.
- Schulze-Tanzil, G., Mobasheri, A., de Souza, P., John, T., Shakibaei, M., 2004b. Loss of chondrogenic potential in dedifferentiated chondrocytes correlates with deficient Shc-Erk interaction and apoptosis. *Osteoarthritis Cartilage* 12, 448–458.
- Sendzik, J., Shakibaei, M., Schafer-Korting, M., Stahlmann, R., 2005. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. *Toxicology* 212, 24–36.
- Shakibaei, M., De Souza, P., 1997. Differentiation of mesenchymal limb bud cells to chondrocytes in alginate beads. *Cell Biol. Int.* 21, 75–86.
- Shakibaei, M., Merker, H.J., 1999. Beta1-integrins in the cartilage matrix. *Cell Tissue Res.* 296, 565–573.
- Shakibaei, M., Stahlmann, R., 2001. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. *Arch. Toxicol.* 75, 97–102.
- Shakibaei, M., Stahlmann, R., 2003. Ultrastructural changes induced by the des-F(6)-quinolone garenoxacin (BMS-284756) and two fluoroquinolones in Achilles tendon from immature rats. *Arch. Toxicol.* 77, 521–526.
- Shakibaei, M., Schroter-Kermani, C., Merker, H.J., 1993. Matrix changes during long-term cultivation of cartilage (organoid or high-density cultures). *Histol. Histopathol.* 8, 463–470.
- Shakibaei, M., De Souza, P., Merker, H.J., 1997. Integrin expression and collagen type II implicated in maintenance of chondrocyte shape in monolayer culture: an immunomorphological study. *Cell Biol. Int.* 21, 115–125.
- Shakibaei, M., John, T., De Souza, P., Rahmanzadeh, R., Merker, H.J., 1999. Signal transduction by beta1 integrin receptors in human chondrocytes in vitro: collaboration with the insulin-like growth factor-I receptor. *Biochem. J.* 342, 615–623.
- Shakibaei, M., Pfister, K., Schwabe, R., Vormann, J., Stahlmann, R., 2000. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. *Antimicrob. Agents Chemother.* 44, 261–266.
- Shakibaei, M., de Souza, P., van Sickle, D., Stahlmann, R., 2001a. Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. *Arch. Toxicol.* 75, 369–374.
- Shakibaei, M., Schulze-Tanzil, G., de Souza, P., John, T., Rahmanzadeh, M., Rahmanzadeh, R., Merker, H.J., 2001b. Inhibition of mitogen-activated protein kinase induces apoptosis of human chondrocytes. *J. Biol. Chem.* 276, 13289–13294.
- Shakibaei, M., Seifarth, C., John, T., Rahmanzadeh, M., Mobasheri, A., 2006. Igf-I extends the chondrogenic potential of human articular chondrocytes in vitro:

- molecular association between Sox9 and Erk1/2. *Biochem. Pharmacol.* 72, 1382–1395.
- Shakibaei, M., John, T., Schulze-Tanzil, G., Lehmann, I., Mobasheri, A., 2007a. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. *Biochem. Pharmacol.* 73, 1434–1445.
- Shakibaei, M., John, T., Seifarth, C., Mobasheri, A., 2007b. Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. *Ann. NY Acad. Sci.* 1095, 554–563.
- Shen, G., 2005. The role of type X collagen in facilitating and regulating endochondral ossification of articular cartilage. *Orthod. Craniofac. Res.* 8, 11–17.
- Short, B., Brouard, N., Occhiodoro-Scott, T., Ramakrishnan, A., Simmons, P.J., 2003. Mesenchymal stem cells. *Arch. Med. Res.* 34, 565–571.
- Shukunami, C., Oshima, Y., Hiraki, Y., 2001. Molecular cloning of tenomodulin, a novel chondromodulin-related gene. *Biochem. Biophys. Res. Commun.* 280, 1323–1327.
- Sledge, S.L., 2001. Microfracture techniques in the treatment of osteochondral injuries. *Clin. Sports Med.* 20, 365–377.
- Solchaga, L.A., Goldberg, V.M., Caplan, A.I., 2001. Cartilage regeneration using principles of tissue engineering. *Clin. Orthop. Relat. Res.* 391 (Suppl.), S161–S170.
- Solchaga, L.A., Penick, K., Porter, J.D., Goldberg, V.M., Caplan, A.I., Welter, J.F., 2005a. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. *J. Cell Physiol.* 203, 398–409.
- Solchaga, L.A., Temenoff, J.S., Gao, J., Mikos, A.G., Caplan, A.I., Goldberg, V.M., 2005b. Repair of osteochondral defects with hyaluronan- and polyester-based scaffolds. *Osteoarthritis Cartilage* 13, 297–309.
- Steadman, J.R., Rodkey, W.G., Briggs, K.K., Rodrigo, J.J., 1999. [The microfracture technic in the management of complete cartilage defects in the knee joint]. *Orthopade* 28, 26–32.
- Tallheden, T., Karlsson, C., Brunner, A., Van Der Lee, J., Hagg, R., Tommasini, R., Lindahl, A., 2004. Gene expression during redifferentiation of human articular chondrocytes. *Osteoarthritis Cartilage* 12, 525–535.
- Tallheden, T., Brittberg, M., Peterson, L., Lindahl, A., 2006. Human articular chondrocytes – plasticity and differentiation potential. *Cells Tissues Organs* 184, 55–67.
- Tamamura, Y., Otani, T., Kanatani, N., Koyama, E., Kitagaki, J., Komori, T., Yamada, Y., Costantini, F., Wakisaka, S., Pacifici, M., Iwamoto, M., Enomoto-Iwamoto, M., 2005. Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. *J. Biol. Chem.* 280, 19185–19195.
- Till, J.E., McCulloch, E.A., 1980. Hemopoietic stem cell differentiation. *Biochim. Biophys. Acta.* 605, 431–459.
- Tsutsumi, S., Shimazu, A., Miyazaki, K., Pan, H., Koike, C., Yoshida, E., Takagishi, K., Kato, Y., 2001. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. *Biochem. Biophys. Res. Commun.* 288, 413–419.
- Tuli, R., Li, W.J., Tuan, R.S., 2003. Current state of cartilage tissue engineering. *Arthritis Res. Ther.* 5, 235–238.
- Ukai, R., Honmou, O., Harada, K., Houkin, K., Hamada, H., Kocsis, J.D., 2007. Mesenchymal stem cells derived from peripheral blood protects against ischemia. *J. Neurotrauma* 24, 508–520.
- Vachon, A., Bramlage, L.R., Gabel, A.A., Weisbrode, S., 1986. Evaluation of the repair process of cartilage defects of the equine third carpal bone with and without subchondral bone perforation. *Am. J. Vet. Res.* 47, 2637–2645.
- von der Mark, K., 1980. Immunological studies on collagen type transition in chondrogenesis. *Curr. Top. Dev. Biol.* 14, 199–225.
- von der Mark, K., Gaus, V., von der Mark, H., Muller, P., 1977. Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. *Nature* 267, 531–532.
- Wagner, W., Wein, F., Seckinger, A., Frankhauser, M., Wirkner, U., Krause, U., Blake, J., Schwager, C., Eckstein, V., Ansoorge, W., Ho, A.D., 2005. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp. Hematol.* 33, 1402–1416.
- Wakitani, S., 2007. Present status and perspective of articular cartilage regeneration. *Yakugaku Zasshi* 127, 857–863.
- Wakitani, S., Goto, T., Pineda, S.J., Young, R.G., Mansour, J.M., Caplan, A.I., Goldberg, V.M., 1994. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. *J. Bone Joint Surg. Am.* 76, 579–592.
- Wakitani, S., Goto, T., Young, R.G., Mansour, J.M., Goldberg, V.M., Caplan, A.I., 1998. Repair of large full-thickness articular cartilage defects with allograft articular chondrocytes embedded in a collagen gel. *Tissue Eng.* 4, 429–444.
- Wakitani, S., Imoto, K., Yamamoto, T., Saito, M., Murata, N., Yoneda, M., 2002. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage* 10, 199–206.
- Watt, S.M., Contreras, M., 2005. Stem cell medicine: umbilical cord blood and its stem cell potential. *Semin Fetal Neonatal Med.* 10, 209–220.
- Wickham, M.Q., Erickson, G.R., Gimble, J.M., Vail, T.P., Guilak, F., 2003. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. *Clin. Orthop. Relat. Res.* 412, 196–212.
- Williams, J.T., Southerland, S.S., Souza, J., Calcutt, A.F., Cartledge, R.G., 1999. Cells isolated from adult

- human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. *Am. Surg.* 65, 22–26.
- Wohl, G., Goplen, G., Ford, J., Novak, K., Hurtig, M., McPherson, R., McGann, L., Schachar, N., Zernicke, R.F., 1998. Mechanical integrity of subchondral bone in osteochondral autografts and allografts. *Can. J. Surg.* 41, 228–233.
- Xian, C.J., Foster, B.K., 2006. Repair of injured articular and growth plate cartilage using mesenchymal stem cells and chondrogenic gene therapy. *Curr. Stem Cell Res. Ther.* 1, 213–229.
- Yamamoto, N., Akamatsu, H., Hasegawa, S., Yamada, T., Nakata, S., Ohkuma, M., Miyachi, E.I., Marunouchi, T., Matsunaga, K., 2007. Isolation of multipotent stem cells from mouse adipose tissue. *J. Dermatol. Sci.* 48, 43–52.
- Yan, H., Yu, C., 2007. Repair of full-thickness cartilage defects with cells of different origin in a rabbit model. *Arthroscopy* 23, 178–187.
- Yoo, J.U., Barthel, T.S., Nishimura, K., Solchaga, L., Caplan, A.I., Goldberg, V.M., Johnstone, B., 1998. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. *J. Bone Joint Surg. Am.* 80, 1745–1757.
- Yoshimoto, H., Shin, Y.M., Terai, H., Vacanti, J.P., 2003. A biodegradable nanofiber scaffold by electrospinning and its potential for bone tissue engineering. *Biomaterials* 24, 2077–2082.
- Zhang, Z., McCaffery, J.M., Spencer, R.G., Francomano, C.A., 2004. Hyaline cartilage engineered by chondrocytes in pellet culture: histological, immunohistochemical and ultrastructural analysis in comparison with cartilage explants. *J. Anat.* 205, 229–237.
- Zheng, M.H., Willers, C., Kirilak, L., Yates, P., Xu, J., Wood, D., Shimmin, A., 2007. Matrix-induced autologous chondrocyte implantation (MACI): biological and histological assessment. *Tissue Eng.* 13, 737–746.
- Zhou, S., Eid, K., Glowacki, J., 2004. Cooperation between TGF-beta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. *J. Bone Miner. Res.* 19, 463–470.
- Zuk, P.A., Zhu, M., Mizuno, H., Huang, J., Futrell, J.W., Katz, A.J., Benhaim, P., Lorenz, H.P., Hedrick, M.H., 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng.* 7, 211–228.
- Zuk, P.A., Zhu, M., Ashjian, P., De Ugarte, D.A., Huang, J.I., Mizuno, H., Alfonso, Z.C., Fraser, J.K., Benhaim, P., Hedrick, M.H., 2002. Human adipose tissue is a source of multipotent stem cells. *Mol. Biol. Cell* 13, 4279–4295.
- Zvaifler, N.J., Marinova-Mutafchieva, L., Adams, G., Edwards, C.J., Moss, J., Burger, J.A., Maini, R.N., 2000. Mesenchymal precursor cells in the blood of normal individuals. *Arthritis Res.* 2, 477–488.